GenMont Biotech Inc (3164) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GenMont Biotech Inc (3164) has a cash flow conversion efficiency ratio of 0.034x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$49.47 Million ≈ $1.56 Million USD) by net assets (NT$1.45 Billion ≈ $45.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GenMont Biotech Inc (3164) liquidity interval to measure how many days the company can operate on defensive assets alone.
GenMont Biotech Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how GenMont Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
GenMont Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GenMont Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Liberty Shoes Limited
NSE:LIBERTSHOE
|
0.117x |
|
Investment and Trading of Real Estate JSC
VN:ITC
|
N/A |
|
InfoBeans Technologies Limited
NSE:INFOBEAN
|
0.143x |
|
Hwacheon Machi
KO:010660
|
-0.024x |
|
Moorim Paper
KO:009200
|
-0.006x |
|
Metagenomi, Inc. Common Stock
NASDAQ:MGX
|
-0.154x |
|
MBL Infrastructure Limited
NSE:MBLINFRA
|
0.003x |
|
Leading Edge Materials Corp
V:LEM
|
-0.032x |
Annual Cash Flow Conversion Efficiency for GenMont Biotech Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of GenMont Biotech Inc from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of GenMont Biotech Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$1.45 Billion ≈ $45.67 Million |
NT$73.60 Million ≈ $2.32 Million |
0.051x | -39.40% |
| 2024-12-31 | NT$1.48 Billion ≈ $46.62 Million |
NT$123.95 Million ≈ $3.90 Million |
0.084x | +250.84% |
| 2023-12-31 | NT$1.45 Billion ≈ $45.66 Million |
NT$34.60 Million ≈ $1.09 Million |
0.024x | -74.09% |
| 2022-12-31 | NT$1.50 Billion ≈ $47.17 Million |
NT$137.95 Million ≈ $4.35 Million |
0.092x | +25.79% |
| 2021-12-31 | NT$1.52 Billion ≈ $48.03 Million |
NT$111.66 Million ≈ $3.52 Million |
0.073x | -8.23% |
| 2020-12-31 | NT$1.48 Billion ≈ $46.69 Million |
NT$118.27 Million ≈ $3.73 Million |
0.080x | +55.11% |
| 2019-12-31 | NT$1.45 Billion ≈ $45.62 Million |
NT$74.52 Million ≈ $2.35 Million |
0.051x | +43.51% |
| 2018-12-31 | NT$1.56 Billion ≈ $49.23 Million |
NT$56.03 Million ≈ $1.77 Million |
0.036x | -36.63% |
| 2017-12-31 | NT$1.37 Billion ≈ $43.19 Million |
NT$77.56 Million ≈ $2.44 Million |
0.057x | +59.70% |
| 2016-12-31 | NT$1.28 Billion ≈ $40.32 Million |
NT$45.34 Million ≈ $1.43 Million |
0.035x | +1161.02% |
| 2015-12-31 | NT$1.50 Billion ≈ $47.27 Million |
NT$-5.01 Million ≈ $-157.84K |
-0.003x | +91.40% |
| 2014-12-31 | NT$1.60 Billion ≈ $50.32 Million |
NT$-62.00 Million ≈ $-1.95 Million |
-0.039x | -132.38% |
| 2013-12-31 | NT$837.28 Million ≈ $26.38 Million |
NT$100.37 Million ≈ $3.16 Million |
0.120x | +538.11% |
| 2012-12-31 | NT$861.62 Million ≈ $27.15 Million |
NT$-23.58 Million ≈ $-742.77K |
-0.027x | -161.99% |
| 2011-12-31 | NT$904.75 Million ≈ $28.50 Million |
NT$39.94 Million ≈ $1.26 Million |
0.044x | -83.72% |
| 2010-12-31 | NT$737.87 Million ≈ $23.25 Million |
NT$200.03 Million ≈ $6.30 Million |
0.271x | +58.78% |
| 2009-12-31 | NT$635.68 Million ≈ $20.03 Million |
NT$108.53 Million ≈ $3.42 Million |
0.171x | +3.44% |
| 2008-12-31 | NT$609.60 Million ≈ $19.21 Million |
NT$100.62 Million ≈ $3.17 Million |
0.165x | +99.72% |
| 2007-12-31 | NT$524.64 Million ≈ $16.53 Million |
NT$43.36 Million ≈ $1.37 Million |
0.083x | +29.07% |
| 2006-12-31 | NT$461.75 Million ≈ $14.55 Million |
NT$29.56 Million ≈ $931.43K |
0.064x | +94.99% |
| 2005-12-31 | NT$290.14 Million ≈ $9.14 Million |
NT$9.53 Million ≈ $300.15K |
0.033x | -- |
About GenMont Biotech Inc
GenMont Biotech Incorporation engages in the research and development, manufacture, and sale of various probiotic health products in Taiwan, Singapore, Mainland Chinese, and internationally. The company offers OEM and ODM services, including functional probiotic raw materials, capsules, powder, tablets, and liquid products. GenMont Biotech Incorporation was founded in 2000 and is based in Tainan … Read more